Related Experiment Video
Updated: Aug 14, 2026
Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
Published on: April 14, 2014
Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab
Eva Costa Arpín1, Tania García Sobrino1, Clara Domínguez Vivero1
1Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain.
Aim:
To evaluate the effect of natalizumab on progression of brain atrophy in multiple sclerosis (MS) patients and to search for a clinical or radiological marker of progression of brain atrophy.
Patients And Methods:
We retrospectively recorded demographic and clinical data, as well as the corpus callosum index (CCI) using MRI, in MS patients treated with natalizumab for 1-4 years.
Results:
In the study population (n = 29), baseline mean CCI was 0.37 ± 0.04 and final CCI 0.36 ± 0.04. 17 patients did not develop brain atrophy during follow-up. There was no statistically significant relationship between progression of atrophy and clinical and radiological parameters.
Conclusion:
Natalizumab may have a neuroprotective effect.
